It is important that we have accurate models for the risk stratification of cancer patients, in order to determine how best to treat them. Here, Jerome Galon, PhD, of Cordeliers Research Center, Paris, France, gives an overview of the immunoscore, an immunological assay that his team developed, which allows for the risk quantification of cancer patients based on adaptive immunity. The immunoscore has proven to be a useful predictor of survival and recurrence of cancer, and may eventually be used by many centers around the world. This video was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.
The immunoscore: a new way of stratifying cancer
